MLICM
IMDX

Metropolitan Life Insurance Company (MetLife)’s Insight Molecular Diagnostics IMDX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,162
Closed -$133K – 2848
2021
Q2 		$133K Buy
1,162
+134
+13% +$13.1K ﹤0.01% 2433
2021
Q1 		$107K Buy
+1,028
New +$97.6K ﹤0.01% 2399

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s IMDX Position: Q3 2021 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Insight Molecular Diagnostics (IMDX) in Q3 2021, closing a stake of 1,162 shares — an estimated $133K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in IMDX in Q1 2021 and held it in 2 quarters. The position peaked at $133K in Q2 2021. 95 funds tracked by Wall St. Rank hold IMDX as of Q3 2021.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Insight Molecular Diagnostics position as of Q3 2021 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 1,162 Insight Molecular Diagnostics shares in Q3 2021, an estimated $133K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Insight Molecular Diagnostics in Q1 2021 and held it in 2 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Insight Molecular Diagnostics position peaked at $133K in Q2 2021.
  • 95 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2021.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q3 2021, filed 15 Nov 2021.